Chemists have engineered a fluorescent molecular probe that lets them watch, stage by stage, how a small molecule shuts down the glycation of a model protein — the non-enzymatic reaction between sugars and proteins that underlies many diabetic complications. In a study published in Discover Molecules, Santu Bhunia, Koushik Chandra and colleagues at Indian research institutions describe how tagging a pseudo C2-symmetric aldazine scaffold with a dansyl fluorophore produced a compound, DVBA-1, that inhibits both fructose-driven and methylglyoxal-driven glycation of bovine serum albumin (BSA) from the earliest Amadori stage through to the formation of advanced cross-linked aggregates.
Glycation begins when a reducing sugar such as fructose reacts with free amino groups on a protein to form an early, reversible Schiff base that rearranges into a more stable ketoamine, the so-called Amadori product. Over time, these intermediates oxidize and fragment into reactive dicarbonyl species such as glyoxal and methylglyoxal, which in turn drive the creation of fluorescent and non-fluorescent cross-linked aggregates known as advanced glycation end-products, or AGEs. Persistent hyperglycemia accelerates this cascade in diabetes, contributing to microvascular damage in the retina, kidney and nerves as well as macrovascular disease. Because AGE formation follows this multi-stage trail, the team reasoned that a stage-spanning inhibitor could serve both as a lead for drug design and as a probe for mapping the mechanism itself.
The starting scaffold, an aldazine or bis-aldimine made by condensing vanillin with hydrazine, had previously shown antiglycation activity in the group’s earlier work on a C2-symmetric compound called VBA-2. In the new study, the researchers coupled dansyl chloride to the para positions of VBA-2, yielding DVBA-1 as a greenish-yellow solid in 92 percent yield. Nuclear magnetic resonance told them something important about the molecule’s shape: the deshielded imine proton at 8.14 ppm and the halving of carbon signals in the 13C spectrum indicated a stable, planar, transoid (s-trans) conformer consistent with the pseudo C2-symmetric structure. This conformational rigidity, the authors argue, is central to how the compound works — a rotamer with limited mobility presents a well-defined spatial arrangement that favors selective binding.
Experimentally, DVBA-1 interfered with glycation at every checkpoint the team measured. In the NBT-based fructosamine assay, the compound lowered the formation of Amadori products by more than 50 percent at 24 micromolar, in a concentration- and time-dependent manner, apparently by competitively blocking fructose’s access to free amino groups. Protein-bound carbonyl content, which fructose-driven glycation raised roughly fourfold above unmodified BSA to 10.31 nanomoles per milligram (and to 12.36 nanomoles per milligram in the methylglyoxal system), fell to 1.13 and 2.72 nanomoles per milligram respectively when 30 micromolar DVBA-1 was co-incubated. Available amino groups, which glycation depleted to 7.66 and 5.91 nanomoles per milligram, were largely preserved at 24.0 and 18.25 nanomoles per milligram in the presence of the inhibitor at 47 degrees Celsius.
The compound also showed signs of acting as a scavenger of methylglyoxal, one of the most damaging reactive dicarbonyl intermediates. When DVBA-1 was incubated with varying concentrations of methylglyoxal, the dansyl absorbance peak blue-shifted and its fluorescence quenched — an observation the authors note is consistent with earlier work by Voziyan and colleagues, and one that suggests the aldazine pharmacophore may react nucleophilically with methylglyoxal, competing for it during glycation and thereby impeding AGE formation. In post-Amadori assays, co-incubation with 0 to 30 micromolar DVBA-1 quenched the characteristic AGE fluorescence at excitation/emission pairs of 370/435 nanometers (fructose system) and 335/388 nanometers (methylglyoxal system) by nearly 50 percent in a dose-dependent fashion, with inhibition comparable to the reference antiglycation drug aminoguanidine in the methylglyoxal system.
Crucially, the dansyl tag itself turned out to be a bystander rather than a participant. In every isolated glycated BSA sample — whether analyzed by steady-state fluorescence, synchronous fluorescence, or three-dimensional excitation-emission matrices — no dansyl emission at its characteristic 498 nanometer maximum was detected, indicating that neither the fluorophore nor the intact compound remained attached to the final cross-linked aggregates. Instead, the evidence points to an early interaction: DVBA-1 binds BSA at the outset of glycation, perturbs the protein’s conformation and glycation microenvironment, and thereby redirects or suppresses the entire downstream cascade. Time-resolved fluorescence supported this dynamic-quenching picture: the average lifetime of glycated BSA formed with 20 micromolar DVBA-1 dropped to 2.24 ± 0.01 nanoseconds from 4.49 ± 0.03 nanoseconds for glycated BSA alone, and fluorescence anisotropy fell from 0.141 ± 0.002 to 0.112 ± 0.002 in the fructose system, indicating restored motional freedom.
Dynamic light scattering quantified how much aggregate formation was curtailed. Untreated BSA showed a hydrodynamic radius of 6.53 ± 0.25 nanometers; glycation swelled this to 40.67 ± 0.41 nanometers in the fructose system and 10.56 ± 0.10 nanometers in the methylglyoxal system. With DVBA-1 present, the radii shrank dramatically to 8.72 ± 0.10 and 9.29 ± 0.10 nanometers respectively. Thioflavin-T and ANS fluorescence, both of which report on β-sheet aggregation and surface hydrophobicity, were quenched by up to 50 percent at 30 micromolar inhibitor, and far-UV circular dichroism showed that the compound partially ameliorated the glycation-driven loss of α-helical content. FTIR spectra revealed small hypsochromic shifts in the amide bands and the sugar-binding-associated peak near 1240 per centimeter, consistent with early-stage conformational interference rather than late-stage attachment.
Where on the protein does this happen? A competitive displacement assay using the standard site markers warfarin, ibuprofen and digoxin pointed to Sudlow’s site I in subdomain IIA as the primary interaction site, with the strongest quenching observed when warfarin competed for that pocket. Molecular docking placed a specific rotameric transoid conformer of DVBA-1 (binding energy −8.4 kilocalories per mole) mostly into subdomain IIA with a small portion reaching subdomain IIIA, stabilized largely by Ï€-alkyl, cation-Ï€ and van der Waals contacts with residues including Trp213, Leu237, Arg256 and Tyr451, plus a few hydrogen bonds to Arg194, Arg198 and Arg217. A 500-nanosecond molecular dynamics simulation confirmed a stable complex: root-mean-square deviations stayed below 0.4 nanometers for both free BSA and the conjugate, the ligand remained lodged between the IIA and IIIA subdomains throughout, and the most populated cluster represented 68 percent of the trajectory — the signature of conformational selection. The MMPBSA binding free energy averaged −48.27 kilocalories per mole, dominated by hydrophobic contributions.
Quantum chemical geometry optimization then explained which conformer does the binding. Of the three transoid-cisoid conformational equilibria modeled, the transoid VA rotamer most closely matched the docked pose, and its compact 19.7-angstrom length — far shorter than the 28.56-angstrom IA or 25.38-angstrom IIIA variants — allows it to fit the pocket spanning subdomains IIA and IIIA. Conformational plots showed DVBA-1 preferring a torsional angle of +165 degrees, analogous to the −151 degrees preference of the parent VBA-2, reinforcing that the unlabeled aldazine pharmacophore, not the dansyl group, drives the conformationally selective binding. The calculated rotational energy barrier for the relevant conformer system was 21.9 kilocalories per mole.
The authors also report in silico drug-likeness predictions for the VBA-2 pharmacophore: compliance with Lipinski’s Rule of Five, a predicted bioavailability score of 0.55, gastrointestinal absorption with marginal blood-brain barrier access, no P-glycoprotein substrate status, minimal cytochrome P450 interference, and a class IV low-toxicity classification with a predicted oral LD50 of 2000 milligrams per kilogram. These are computational predictions, not experimental pharmacology, and all of the biological results come from an in vitro BSA model rather than living systems — important caveats for any therapeutic framing. Still, the integrated picture is striking: by fusing a fluorescent reporter to a rigid, conformationally biased pharmacophore, the team could show that a single early binding event near BSA’s sugar-binding domain propagates into protection across the entire glycation timeline, offering a stepwise analytical strategy for designing the next generation of antiglycation agents.
Subject of Research: Conformation-selective inhibition of protein glycation by a dansyl-labeled aldazine molecular probe
Article Title: Labeling dansyl molecular probe in aldazines to decipher conformational selected inhibition pathway from early to advanced glycation
Article References: Bhunia, S., Bankura, A., Hansda, C. C., Das, S., Sasmal, S., Dutta, S., Jana, R., & Chandra, K. (2026). Labeling dansyl molecular probe in aldazines to decipher conformational selected inhibition pathway from early to advanced glycation. Discover Molecules, 3(1), Article 21. https://doi.org/10.1007/s44345-026-00059-7
Image Credits: AI Generated
DOI: 10.1007/s44345-026-00059-7
Keywords: glycation, advanced glycation end-products, dansyl probe, aldazine, bovine serum albumin, methylglyoxal, fructose, conformational selection, molecular docking, molecular dynamics simulation, diabetes, fluorescence spectroscopy
News Source: Bethany Barker. (October 29, 2026). Dansyl-Labeled Aldazine Probe Reveals How Conformation Blocks Protein Glycation. Scienmag.
